Clinical Trial Update: Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of Combretastatin A4 Phosphate for choroidal neovascularization secondary to pathologic myopia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Pathologic Myopia

Drugs mentioned

• Combretastatin A4 phosphate (combretastatin A4 phosphate)

Snippet

Sponsor: Mateon Therapeutics | Conditions: Choroidal Neovascularization, Myopia, Degenerative | Phase 2 | Status: COMPLETED